115016-99-4Relevant articles and documents
CONTROLLED RELEASE COMPOSITIONS AND METHODS FOR USING SAME
-
Page 30, (2010/02/06)
Pharmaceutical preparations adapted for mucosal delivery, preferably for nasal delivery, which can be easily and safely used over days to weeks with minimal side effects. The pharmaceutical preparations comprise microcapsules comprising at least one pharmaceutically active agent. The microcapsules provide controlled release of the pharmaceutically active agent. Cytotoxicity is avoided for cytotoxic pharmaceutically active agents and/or for cytotoxic dosages by one or more of the following: (a) manipulating the mucosal transport rate of the pharmaceutically active agent through the mucosal bodies to achieve a transport rate which is substantially the same as the controlled release rate, and/or (b) selecting only a most active and/or less cytotoxic enantiomer of the pharmaceutically active agent for use in the pharmaceutical preparation.
Endor Studies of Cation Radicals from Pharmacologically Active Phenothiazines
Helle, N.,Kurreck, H.,Bock, M.,Kieslich, W.
, p. 964 - 970 (2007/10/02)
A variety of substituted phenothiazine cation radicals, including those from pharmacologically active derivatives, e.g. chloropromazine, alimemazine and laevomepromazine, have been studied by means of ENDOR and TRIPLE resonace spectroscopy.These techniques allowed accurate determinations of hyperfine coupling constants, including their signs.Conclusions concerning molecular structure (e.g. twist angles) could be drawn, supporting previous investigations of the interrelationship of molecular conformations with the pharmacological potential, i.e. neuroleptic, antihistaminic or anti-Parkinsonian.